The use of quorum-sensing blockers as therapeutic agents for the control of biofilm-associated infections.
The development of novel antimicrobial compounds is required to treat the growing number of infections where antibiotic resistance is a serious threat, especially in situations where biofilms are involved. Antibiotic resistance is the result of two factors: first, through the development of specific antibiotic resistance, due to either mutation or the acquisition of antibiotic resistance genes; and second, by the innate tolerance of bacterial biofilms. Bacterial control, through the inhibition of bacterial cell-cell communication systems which are involved in the regulation of virulence factor production, host colonization, and biofilm formation, is discussed in this review. Specifically, this review presents current studies on the development of quorum-sensing inhibitors for the control of bacterial infections.
Rice
Scott A
SA
The School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW 2052, Australia.
McDougald
Diane
D
Kumar
Naresh
N
Kjelleberg
Staffan
S
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D018441:Biofilms / Q000187:drug effects; D006714:Homoserine / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D007783:Lactones / Q000037:antagonists & inhibitors; D008025:Ligases / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects
D000890:Anti-Infective Agents; D007783:Lactones; C091088:N-octanoylhomoserine lactone; D006714:Homoserine; D008025:Ligases; C449816:N-acylhomoserine lactone synthase